SCHEMBL2937065

SCHEMBL2937065

O=C1CN(Cc2ccnc(N3CCCCC3)c2)C(=O)N1c1ccc(S(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
OPRM1 P35372 1/20 0.38
OPRL1 P41146 1/20 0.38
IGF1R P08069 2/20 0.38
PPARD Q03181 2/20 0.36
PPARA Q07869 2/20 0.36
ENPP2 Q13822 2/20 0.36
HCRTR1 O43613 2/20 0.36
HCRTR2 O43614 2/20 0.36
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
NMT1 P30419 1/20 0.34
KLKB1 P03952 3/20 0.33
TLR7 Q9NYK1 2/20 0.33
KLK1 P06870 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2939931 0.91 HCRTR1 (0.40) LMNAMAPK1HTTSMN1; SMN2OPRM1
SCHEMBL2939856 0.85 PPARD (0.39) LMNAMAPK1HTTSMN1; SMN2IGF1R
SCHEMBL2937377 0.84 IGF1R (0.43) LMNAMAPK1HTTSMN1; SMN2IGF1R
SCHEMBL2935236 0.84 CCR6 (0.42) SMN1; SMN2OPRM1OPRL1PPARDPPARA
SCHEMBL2938847 0.84 IGF1R (0.46) OPRM1OPRL1IGF1R
SCHEMBL2939603 0.84 HCRTR1 (0.39) IGF1RPPARDPPARAENPP2HCRTR1
SCHEMBL2940645 0.84 IGF1R (0.40) LMNAMAPK1HTTSMN1; SMN2IGF1R
SCHEMBL2942564 0.84 IGF1R (0.43) LMNAMAPK1HTTSMN1; SMN2IGF1R
SCHEMBL2936080 0.84 IGF1R (0.43) LMNAMAPK1HTTSMN1; SMN2IGF1R
SCHEMBL2938554 0.84 PPARD (0.43) LMNAMAPK1HTTSMN1; SMN2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 LMNA 1988/4885MAPK1 53/4885HTT 3931/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA LMNA 2970/4885MAPK1 42/4885HTT 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.